Fig. 4

Tumor-specific and IFN-g producing peripheral blood lymphocytes measured by ELISpot at baseline and 2 weeks after the second ilixadencel dose. A direct ex vivo interferon gamma ELISpot analysis was performed and number of spots were counted. Samples were analyzed in triplicates, and mean response was calculated. In a baseline values are compared with values obtained 14 days after second administration and are shown for 9 out of 11 evaluated patients whereas in (b), baseline values and values obtained 14 days after second administration have been normalized to a negative control sample and are shown for 3 of the evaluated patients